Earnings summaries and quarterly performance for KalVista Pharmaceuticals.
Executive leadership at KalVista Pharmaceuticals.
Benjamin L. Palleiko
Detailed
Chief Executive Officer
CEO
BA
Bilal Arif
Detailed
Chief Operating Officer
BP
Brian Piekos
Detailed
Chief Financial Officer
CM
Christopher M. Yea
Detailed
Chief Development Officer
LA
Linea Aspesi
Detailed
Chief People Officer
NS
Nicole Sweeny
Detailed
Chief Commercial Officer
PK
Paul K. Audhya
Detailed
Chief Medical Officer
Board of directors at KalVista Pharmaceuticals.
Research analysts who have asked questions during KalVista Pharmaceuticals earnings calls.
MR
Maury Raycroft
Jefferies
5 questions for KALV
Also covers: ABEO, ALNY, ARWR +11 more
Paul Matteis
Stifel
3 questions for KALV
Also covers: ABOS, ACAD, ALKS +11 more
PS
Pete Stavropoulos
Cantor Fitzgerald
3 questions for KALV
Also covers: ABOS, ALEC, ARCT +7 more
SB
Serge Belanger
Needham & Company
3 questions for KALV
Also covers: AMPH, ARQT, BCRX +12 more
SK
Stacy Ku
TD Cowen
3 questions for KALV
Also covers: AUPH, BCRX, RVNC +3 more
TA
Tazeen Ahmad
Bank of America
3 questions for KALV
Also covers: ACAD, ALNY, APLS +20 more
C
Catherine
Citizens
2 questions for KALV
Also covers: OCUL
DC
Debanjana Chatterjee
JonesTrading Institutional Services
2 questions for KALV
Also covers: ABSI, CLSD, EYPT +2 more
DC
Devanjana Chatterjee
Jones
2 questions for KALV
JS
Joe Schwartz
Leerink Partners
2 questions for KALV
Also covers: BMRN, PTGX, WVE
JW
John Wallman
Citizens Bank
2 questions for KALV
M
Matthew
Stifel
2 questions for KALV
SB
Sergey Balintur
Needham & Company
2 questions for KALV
SK
Stacy Koo
TV Co
2 questions for KALV
William Dubin
Leerink
2 questions for KALV
Catherine Okoukoni
Citizens JMP
1 question for KALV
Also covers: ALT, CRNX, MDGL +2 more
WS
Will Soghikian
Leerink Partners
1 question for KALV
Also covers: AUPH, RARE, TVTX
Recent press releases and 8-K filings for KALV.
KalVista Pharmaceuticals Launches EKTERLY in US and Germany, Reports Strong Initial Sales
KALV
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- KalVista Pharmaceuticals has launched EKTERLY (sebetralstat), the first and only oral on-demand therapy for hereditary angioedema (HAE), in the US and Germany, with approvals in seven key global markets including the US, EU, UK, Switzerland, Australia, Japan, and Singapore.
- From its US launch on July 7, 2025, through December 31, 2025, EKTERLY generated ~$49M in unaudited global net product revenue, with 1,318 patient start forms received and 580 unique prescribers in the US.
- The company is pursuing a pediatric expansion for EKTERLY, with an NDA filing for children aged 2-11 years expected in Q3 2026 and an anticipated launch in 2027.
- KalVista aims to expand its portfolio by developing, acquiring, or in-licensing additional innovative therapies for rare diseases, supported by a strong financial foundation and IP protection into the 2040s.
- The current U.S. HAE market is valued at $650M, with a total addressable market of $1.5B with branded pricing and increased treatment rates, which EKTERLY is poised to capture.
6 days ago
KalVista Pharmaceuticals Reports Preliminary Q4 and Full Year 2025 EKTERLY Revenue
KALV
Earnings
Product Launch
Revenue Acceleration/Inflection
- KalVista Pharmaceuticals announced preliminary unaudited global net product revenue for EKTERLY of approximately $35 million for the fourth quarter of 2025 and $49 million for the full year 2025.
- Since its US commercial launch on July 7, 2025, EKTERLY has received 1,318 patient start forms and activated 580 unique prescribers in the US through December 31, 2025.
- The company is experiencing strong early adoption in Germany and plans to expand into other major markets during 2026, including a partnership with Multicare Pharma to commercialize sebetralstat in Latin America.
- KalVista expects to file a new drug application for pediatric HAE patients aged 2-11 years in the third quarter of 2026, with a US launch anticipated in 2027.
7 days ago
KalVista Pharmaceuticals Provides Preliminary Q4 and Full Year 2025 EKTERLY Revenue Results
KALV
Earnings
Product Launch
New Projects/Investments
- KalVista Pharmaceuticals reported unaudited global net product revenue for EKTERLY of approximately $35 million for the fourth quarter and $49 million for the full year 2025.
- The US commercial launch of EKTERLY, initiated on July 7, 2025, has resulted in 1,318 patient start forms and 580 unique prescribers in the US through December 31, 2025.
- EKTERLY, approved in seven global markets, has demonstrated strong early adoption in Germany, and KalVista has partnered with Multicare Pharma for commercialization in Latin America.
- KalVista expects to file a new drug application for EKTERLY in pediatric HAE patients aged 2-11 years in the third quarter of 2026, with a US launch anticipated in 2027.
7 days ago
KalVista Pharmaceuticals Announces Japanese Approval for EKTERLY®
KALV
Product Launch
- KalVista Pharmaceuticals announced the marketing and manufacturing approval of EKTERLY® (sebetralstat) in Japan by the Ministry of Health, Labor and Welfare (MHLW).
- EKTERLY is the first and only oral on-demand treatment for acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older approved in Japan.
- Kaken Pharmaceutical Co., Ltd. will commercialize EKTERLY in Japan, with a launch planned shortly after its listing on the Japanese National Health Insurance System (NHI).
- This approval, based on the phase 3 KONFIDENT clinical trial, marks the seventh regulatory approval for EKTERLY across major global markets since July 3, 2025.
Dec 22, 2025, 11:00 AM
KalVista Provides Update on Ekterly Launch and Market Penetration
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals launched Ekterly, the first oral therapy for on-demand treatment of acute HAE attacks, in July following FDA approval.
- The company has seen rapid uptake, with over 1,000 patients on therapy, representing comfortably over 10% of the marketplace.
- KalVista reported $13.7 million in revenue last quarter, primarily reflecting actual end-user demand, with severe disease patients showing high refill frequency (e.g., three to four weeks).
- The company anticipates maintaining market leadership despite upcoming competitor data, citing Ekterly's early market entry, high patient satisfaction, and the distinct design of its clinical trials.
- International expansion includes a first shipment to Germany in October, with planned launches in the U.K. in H1 2026 and Japan in Q1 2026, though XUS markets are expected to price at a fraction of U.S. pricing (e.g., 20% of U.S. price).
Nov 19, 2025, 1:30 PM
KalVista Pharmaceuticals Provides Update on EKTERLY Launch and Commercialization
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals launched EKTERLY, an oral therapy for acute HAE attacks, in July following FDA approval, marking a substantial advance in treatment.
- As of November 2025, over 1,000 patients are on EKTERLY therapy, representing 12-13% of the marketplace, with rapid uptake.
- The company reported $13.7 million in revenue last quarter, primarily driven by end-user demand for EKTERLY.
- International expansion plans include the first shipment to Germany in October, with launches expected in the U.K. in H1 2026 and Japan in Q1 2026; XUS markets are projected to contribute 20% of global revenue long-term.
- KalVista does not anticipate upcoming Pharvaris Phase 3 data to impact EKTERLY's commercial trajectory due to significant differences in study design and EKTERLY's established market position.
Nov 19, 2025, 1:30 PM
KalVista Pharmaceuticals Discusses EKTERLY Launch and Market Trajectory
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals launched EKTERLY, an oral therapy for the on-demand treatment of acute attacks of HAE, in July after FDA approval.
- As of November 19, 2025, over 1,000 patients are on therapy, representing 12%-13% of the marketplace, with 937 start forms reported earlier, indicating extraordinarily fast uptake.
- The company reported $13.7 million in revenue for the last quarter, primarily reflecting actual end-user demand for EKTERLY.
- Refills are evolving, with severe disease patients (15%-20% of the total patient population) refilling at a high frequency of three to four weeks, often with multiple cartons.
- International launches include the first shipment to Germany in October, with planned launches in the U.K. in the first half of 2026 and Japan in the first quarter of 2026.
Nov 19, 2025, 1:30 PM
KalVista Pharmaceuticals Reports Strong Initial Commercial Performance for EKTERLY
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals reported its first full commercial quarter for EKTERLY, the first and only oral therapy for HAE attacks, following its approval on July 3 and launch on July 7.
- The launch has demonstrated strong uptake, with 10%-12% of patients converting to EKTERLY in less than four months, resulting in revenues meaningfully exceeding expectations.
- The company is consistently adding approximately 200-220 new patients per month, with early adopters largely being high-attack rate patients who show higher refill rates.
- Payer coverage is developing as anticipated, with major formularies expected by early 2026, and international expansion is underway, including a successful launch in Germany.
- KalVista plans to grow into a leading rare disease commercial entity, with an NDA filing for the pediatrics indication anticipated in Q3 next year.
Nov 12, 2025, 1:40 PM
KalVista Pharmaceuticals Discusses Strong EKTERLY Launch and Global Expansion
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- EKTERLY, the first oral therapy for HAE attacks, was approved on July 3 and launched on July 7, 2025. Within less than four months, 10%-12% of patients have already converted to EKTERLY.
- The company reported its first full quarter as a commercial entity, with revenues meaningfully beyond expectations, primarily driven by actual patient demand.
- Payer coverage is progressing as anticipated, with smaller payers adopting policies faster, and the vast majority of prescriptions in the third quarter were medical exceptions.
- Half of the patients switching to EKTERLY self-reported two or more attacks per month, validating the company's theory about a high-attack rate population that is highly receptive to the drug.
- KalVista launched EKTERLY in Germany last month and plans further European expansion and global partnerships, aiming to become a leading rare disease commercial entity.
Nov 12, 2025, 1:40 PM
KalVista Pharmaceuticals Reports Strong Initial EKTERLY Launch Performance
KALV
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- KalVista Pharmaceuticals successfully launched EKTERLY, the first and only oral therapy for HAE attacks, on July 7, and reported its first full commercial quarter with revenues "meaningfully beyond where people thought they would".
- In less than four months, 10%-12% of patients have already converted to EKTERLY, with about half of these patients self-reporting two or more attacks a month, indicating strong uptake among high-need individuals.
- Payer coverage is progressing as anticipated, with smaller formularies adopting policies faster, while larger payers are expected to finalize policies by early 2026; the majority of prescriptions in the first commercial quarter were obtained via medical exception.
- The company has begun international expansion, launching EKTERLY in Germany last month with sales exceeding expectations, and plans to launch in the UK next year, though ex-US markets are expected to contribute about 20% of total revenue with significantly lower pricing power compared to the US.
Nov 12, 2025, 1:40 PM
Quarterly earnings call transcripts for KalVista Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more